Summary
Definition
History and exam
Key diagnostic factors
- sexo masculino
- história de doença inflamatória intestinal
Other diagnostic factors
- idade 25-45 anos
- dor abdominal
- prurido
- fadiga
- perda de peso
- febre
- icterícia
- esteatorreia
- esplenomegalia
- ascite
- encefalopatia
Risk factors
- sexo masculino
- doença inflamatória intestinal (DII)
- predisposição genética
Diagnostic tests
1st tests to order
- fosfatase alcalina sérica
- gama-glutamiltransferase sérica
- aminotransferases séricas (aspartato aminotransferase, alanina aminotransferase)
- bilirrubina total sérica
- albumina sérica
- Hemograma completo
- tempo de protrombina
- ultrassonografia abdominal
- colangiopancreatografia por ressonância magnética (CPRM)
- imunoglobulina G4 (IgG4) sérica
Tests to consider
- colangiopancreatografia retrógrada endoscópica (CPRE)
- IgM sérica
- anticorpo antinuclear
- anticorpo antimúsculo liso
- anticorpo antimitocondrial
- tomografia computadorizada (TC) abdominal
- biópsia hepática
- densitometria óssea
- colonoscopia
- exames não invasivos baseados em imagens para fibrose
Treatment algorithm
doença inicial
doença hepática em estágio terminal
Contributors
Authors
S. Ian Gan, MD, FRCPC
Associate Clinical Professor
Vancouver General Hospital
University of British Columbia
Vancouver
BC
Disclosures
SIG declares that he has no competing interests.
Nawaf Tareq Aboalfaraj, MBBS, FRCPC
Advanced Therapeutic Endoscopy Fellow
McGill University
Montreal
QC
Disclosures
NTA declares that he has no competing interests.
Acknowledgements
Dr S. Ian Gan and Dr Nawaf Tareq Aboalfaraj would like to gratefully acknowledge Dr Kris V. Kowdley and Dr Christine Schlenker, the previous contributors to this topic.
Disclosures
KVK is a member of the speakers bureau of Axcan Pharma, manufacturer of Urso250 and Urso Forte, and gives one or two lectures a year on treatment of cholestatic liver diseases. KVK has also received funding from the NIH for a research study of Urso in PSC. CS declares that she has no competing interests.
Peer reviewers
LIsa Forman, MD
Professor of Medicine
University of Colorado
Aurora
CO
Disclosures
LF declares that she has no competing interests.
James Neuberger, BM, BCh
Consultant Physician
Liver Unit
Queen Elizabeth Hospital
Birmingham
UK
Disclosures
JN declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
European Association for the Study of the Liver. EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol. 2022 Sep;77(3):761-806.Full text Abstract
Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702.Full text
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010 Feb;51(2):660-78.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials
- Colangite esclerosante secundária
- Colangite relacionada à imunoglobulina G4 (IgG4)
- Hepatite autoimune
More DifferentialsDiretrizes
- EASL clinical practice guidelines on liver transplantation
- ACR Appropriateness Criteria: abnormal liver function tests
More GuidelinesCalculadoras
Escore MELDNa (para fins de listagem de transplantes de fígado, não é adequado para pacientes com menos de 12 anos de idade ) (unidades SI)
Mais CalculadorasConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal